A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naive Adult Patients With ALK-activated Non-small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ASCEND III
- Sponsors Novartis Pharmaceuticals
- 29 Nov 2017 The trial has been completed in Spain.
- 19 Jul 2017 Planned End Date changed from 1 Jun 2017 to 29 Dec 2017.
- 19 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 29 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History